Yahoo · Aug 31, 2026
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
Iadademstat is under clinical development in acute myeloid leukemia (AML), including in combination with gilteritinib in the Phase Ib FRIDA trial in patients with FLT3-mutated relapsed/refractory (R/R) AML FRIDA data presented at EHA-2026 showed a high composite complete remission (CRc) rate of 67% in heavily pretreated FLT3-mutated R/R AML patients, together with a favorable safety profile MADRID and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733

